Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy

References

• Chavda VP, Baviskar KP, Vaghela DA, Raut SS, Bedse AP. Nasal sprays for treating COVID-19: a scientific note. Pharmacol Rep. 2023;75(2):249–6. doi:10.1007/s43440-023-00463-7.
   PubMed Web of Science ®Google Scholar
• Parray HA, Shukla S, Perween R, Khatri R, Shrivastava T, Singh V, Murugavelu P, Ahmed S, Samal S, Sharma C, et al. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol. 2021;105(16–17):6315–32. doi:10.1007/s00253-021-11488-4.
   PubMed Web of Science ®Google Scholar
• Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X, et al. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J Infect Dis. 2011;203(8):1063–72. doi:10.1093/infdis/jiq168.
   PubMed Web of Science ®Google Scholar
• He F, Kumar SR, Syed Khader SM, Tan Y, Prabakaran M, Kwang J. Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res. 2013;100(1):207–14. doi:10.1016/j.antiviral.2013.08.003.
   PubMed Web of Science ®Google Scholar
• Ye J, Shao H, Hickman D, Angel M, Xu K, Cai Y, Song H, Fouchier RAM, Qin A, Perez DR, et al. Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin Vaccine Immunol. 2010;17(9):1363–70. doi:10.1128/CVI.00002-10.
   PubMedGoogle Scholar
• Casadevall A, Focosi D. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients is a public health concern. J Clin Invest. 2023;133(6). doi:10.1172/JCI168603.
   PubMed Web of Science ®Google Scholar
• Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies. Antimicrob Agents Chemother. 2015;59(7):4162–72. doi:10.1128/AAC.00290-15.
   PubMed Web of Science ®Google Scholar
• Sun T, Wang Y, Zou P, Wang Q, Liu J, Liu W, Huang J, Wu F. M2e-specific antibodies protect against influenza PR8 virus in an isotype and route dependent manner. J Med Virol. 2023;95:e28721. doi:10.1002/jmv.28721.
   PubMed Web of Science ®Google Scholar
• Michelini Z, Minkoff JM, Yang J, Negri D, Cara A, Hanson BJ, Salvatore M. Integrase-defective lentiviral vectors for delivery of monoclonal antibodies against influenza. Viruses. 2020;12(12):12. doi:10.3390/v12121460.
   Web of Science ®Google Scholar
• Mucker EM, Wollen-Roberts SE, Kimmel A, Shamblin J, Sampey D, Hooper JW, Geisbert T. Intranasal monkeypox marmoset model: prophylactic antibody treatment provides benefit against severe monkeypox virus disease. PLoS Negl Trop Dis. 2018;12(6):e0006581. doi:10.1371/journal.pntd.0006581.
   PubMed Web of Science ®Google Scholar
• Jacque E, Chottin C, Laubreton D, Nogre M, Ferret C, de Marcos S, Baptista L, Drajac C, Mondon P, De Romeuf C, et al. Hyper-enriched anti-RSV immunoglobulins nasally administered: a promising approach for respiratory syncytial virus prophylaxis. Front Immunol. 2021;12:683902. doi:10.3389/fimmu.2021.683902.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang G, Li N, Wang Y, Zhu Q, Chu H, Wu W, Tan Y, Yu F, Su X-D, et al. Structural insights into immunoglobulin M. Science. 2020;367(6481):1014–17. doi:10.1126/science.aaz5425.
   PubMed Web of Science ®Google Scholar
• Kumar N, Arthur CP, Ciferri C, Matsumoto ML. Structure of the secretory immunoglobulin a core. Science. 2020;367(6481):1008–14. doi:10.1126/science.aaz5807.
   PubMed Web of Science ®Google Scholar
• Vonarburg C, Loetscher M, Spycher MO, Kropf A, Illi M, Salmon S, Roberts S, Steinfuehrer K, Campbell I, Koernig S, et al. Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates. Respir Res. 2019;20(1):99. doi:10.1186/s12931-019-1057-3.
   PubMedGoogle Scholar
• Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, Cipolla M, Hoffmann HH, Oliveira TY, Oren DA, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2020;13(577):33288661.
   Web of Science ®Google Scholar
• Moroni-Zentgraf P, Usmani OS, Halpin DMG. Inhalation devices. Can Resp J. 2018;2018:5642074. doi:10.1155/2018/5642074.
   PubMed Web of Science ®Google Scholar
• Kane C, O’Neil K, Conk M, Picha K. Inhalation delivery of protein therapeutics. Inflamm Allergy Drug Targets. 2013;12(2):81–7. doi:10.2174/1871528111312020002.
   PubMedGoogle Scholar
• Respaud R, Marchand D, Parent C, Pelat T, Thullier P, Tournamille JF, Viaud-Massuard M-C, Diot P, Si-Tahar M, Vecellio L, et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs. 2014;6(5):1347–55. doi:10.4161/mabs.29938.
   PubMed Web of Science ®Google Scholar
• Mayor A, Thibert B, Huille S, Respaud R, Audat H, Heuzé-Vourc’h N. Inhaled antibodies: formulations require specific development to overcome instability due to nebulization. Drug Deliv Transl Res. 2021;11(4):1625–33. doi:10.1007/s13346-021-00967-w.
   PubMed Web of Science ®Google Scholar
• Faghihi H, Najafabadi AR, Vatanara A. Optimization and characterization of spray-dried IgG formulations: a design of experiment approach. DARU. 2017;25:22. doi:10.1186/s40199-017-0187-8.
   PubMed Web of Science ®Google Scholar
• Cleland JL, Jones AJ. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm Res. 1996;13(10):1464–75. doi:10.1023/A:1016063109373.
   PubMed Web of Science ®Google Scholar
• Mumenthaler M, Hsu CC, Pearlman R. Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator. Pharm Res. 1994;11(1):12–20. doi:10.1023/A:1018929224005.
   PubMed Web of Science ®Google Scholar
• Jayasundera M, Adhikari B, Adhikari R, Aldred P. The effects of proteins and low molecular weight surfactants on spray drying of model sugar-rich foods: powder production and characterisation. J Food Eng. 2011;104(2):259–71. doi:10.1016/j.jfoodeng.2010.12.017.
   Web of Science ®Google Scholar
• Burgess G, Boyce M, Jones M, Larsson L, Main MJ, Morgan F, Phillips P, Scrimgeour A, Strimenopoulou F, Vajjah P, et al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018;35:67–75. doi:10.1016/j.ebiom.2018.07.035.
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckland, NZ). 2015;8:131–9. doi:10.2147/MDER.S48888.
   PubMedGoogle Scholar
• Liao YH, Brown MB, Jones SA, Nazir T, Martin GP. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. Int J Pharm. 2005;304(1–2):29–39. doi:10.1016/j.ijpharm.2005.07.013.
   PubMedGoogle Scholar
• Fathe K, Ferrati S, Moraga-Espinoza D, Yazdi A, Smyth HD. Inhaled biologics: from preclinical to product approval. Curr Pharm Des. 2016;22(17):2501–21. doi:10.2174/1381612822666160210142910.
   PubMed Web of Science ®Google Scholar
• Liang W, Pan HW, Vllasaliu D, Lam JKW. Pulmonary delivery of biological drugs. Pharmaceutics. 2020;12(11):12. doi:10.3390/pharmaceutics12111025.
   Web of Science ®Google Scholar
• Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, Ng DC, Biswas S, Zou J, Liu Y, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595(7869):718–23. doi:10.1038/s41586-021-03673-2.
   PubMed Web of Science ®Google Scholar
• Lu J, Yin Q, Pei R, Zhang Q, Qu Y, Pan Y, Sun L, Gao D, Liang C, Yang J, et al. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants. Virol Sin. 2022;37(2):238–47. doi:10.1016/j.virs.2022.02.005.
   PubMed Web of Science ®Google Scholar
• Cao X, Maruyama J, Zhou H, Fu Y, Kerwin L, Powers C, Sattler RA, Manning JT, Singh A, Lim R, et al. Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies. Sci Rep. 2022;12(1):15517. doi:10.1038/s41598-022-19780-7.
   PubMed Web of Science ®Google Scholar
• Piepenbrink MS, Park JG, Deshpande A, Loos A, Ye C, Basu M, Sarkar S, Khalil AM, Chauvin D, Woo J, et al. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody. PLoS Pathog. 2022;18(7):e1010691. doi:10.1371/journal.ppat.1010691.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang H, Li T, Chen S, Luo F, Zhou J, Zheng P, Song S, Wu Y, Jin T, et al. A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery. Sig Transduct Target Ther. 2022;7:301. doi:10.1038/s41392-022-01135-3.
   PubMed Web of Science ®Google Scholar
• Halwe S, Kupke A, Vanshylla K, Liberta F, Gruell H, Zehner M, Rohde C, Krähling V, Gellhorn Serra M, Kreer C, et al. Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection. Viruses. 2021;13(8):1498. doi:10.3390/v13081498.
   PubMed Web of Science ®Google Scholar
• Jia J, Yin Z, Zhang X, Li H, Meng D, Liu Q, Wang H, Han M, Suo S, Liu Y, et al. Feasibility studies of nebulized SARS-CoV-2 neutralizing antibody in mice and cynomolgus monkeys. Pharm Res. 2022;39(9):2191–201. doi:10.1007/s11095-022-03340-9.
   PubMed Web of Science ®Google Scholar
• Seow HC, Cai JP, Pan HW, Luo C, Wen K, Situ J, Wang K, Cao H, Leung SWS, Yuan S, et al. Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation. J Control Release. 2023;358:128–41. doi:10.1016/j.jconrel.2023.04.029.
   PubMed Web of Science ®Google Scholar
• Lin Y, Yue S, Yang Y, Yang S, Pan Z, Yang X, Gao L, Zhou J, Li Z, Hu L, et al. Nasal spray of neutralizing monoclonal antibody 35B5 confers potential prophylaxis against severe acute respiratory syndrome coronavirus 2 variants of concern: a small-scale clinical trial. Clin Infect Dis. 2023;76:e336–e41. doi:10.1093/cid/ciac448.
   PubMedGoogle Scholar
• Song R, Zeng G, Yu J, Meng X, Chen X, Li J, et al. Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study. Emerging Microbes Infect. 2023:2212806. doi:10.1080/22221751.2023.2212806.
   PubMed Web of Science ®Google Scholar
• BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study. [accessed 2023 Jun 6]. https://www.lumen.bio/news/barda-funded-intranasal-antibody-cocktail-covid-19-shows-promise-preclinical-study.
   Google Scholar
• Jester BW, Zhao H, Gewe M, Adame T, Perruzza L, Bolick DT, Agosti J, Khuong N, Kuestner R, Gamble C, et al. Development of spirulina for the manufacture and oral delivery of protein therapeutics. Nat Biotechnol. 2022;40(6):956–64. doi:10.1038/s41587-022-01249-7.
   PubMed Web of Science ®Google Scholar
• Tabakh H, Jester BW, Zhao H, Kuestner R, Khuong N, Shanitta C, Takeuchi R, Roberts J. Protocol for the transformation and engineering of edible algae Arthrospira platensis to generate heterologous protein-expressing strains. STAR Protocols. 2023;4:102087. doi:10.1016/j.xpro.2023.102087.
   PubMedGoogle Scholar
• Markham A. Brolucizumab: first approval. Drugs. 2019;79:1997–2000. doi:10.1007/s40265-019-01231-9.
   PubMed Web of Science ®Google Scholar
• GM T, Gauthier CD, Murphy L, Lanser TB, Paul A, Matos KTF, Mangani D, Izzy S, Rezende RM, Healy BC, et al. Nasal administration of anti-CD3 mAb (foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19. Proc Natl Acad Sci USA. 2023;120:e2220272120.
   PubMed Web of Science ®Google Scholar
• Minenkova O, Santapaola D, Milazzo FM, Anastasi AM, Battistuzzi G, Chiapparino C, Rosi A, Gritti G, Borleri G, Rambaldi A, et al. Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. Mol Ther. 2022;30(5):1979–93. doi:10.1016/j.ymthe.2022.02.013.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, Bendahman N, Hammers R. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–8. doi:10.1038/363446a0.
   PubMed Web of Science ®Google Scholar
• Muyldermans S, Cambillau C, Wyns L. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci. 2001;26(4):230–5. doi:10.1016/S0968-0004(01)01790-X.
   PubMed Web of Science ®Google Scholar
• Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, Reed DS, Crossland NA, Shi Y, Duprex WP, et al. Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci Adv. 2021;7. doi:10.1126/sciadv.abh0319.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhang X, Zeng W, Zhou J, Chi X, Chen S, Zheng P, Wang M, Wu Y, Zhao D, et al. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. Cell Discovery. 2022;8(1):132. doi:10.1038/s41421-022-00497-w.
   PubMed Web of Science ®Google Scholar
• Haga K, Takai-Todaka R, Matsumura Y, Song C, Takano T, Tojo T, Nagami A, Ishida Y, Masaki H, Tsuchiya M, et al. Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model. PLoS Pathog. 2021;17(10):e1009542. doi:10.1371/journal.ppat.1009542.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang Y, Cheng L, Ni F, Zhu L, Ma S, Huang B, Ji M, Hu H, Li Y, et al. Short-term instantaneous prophylaxis and efficient treatment against SARS-CoV-2 in hACE2 mice conferred by an intranasal nanobody (Nb22). Front Immunol. 2022;13:865401. doi:10.3389/fimmu.2022.865401.
   PubMed Web of Science ®Google Scholar
• Titong A, Gallolu Kankanamalage S, Dong J, Huang B, Spadoni N, Wang B, Wright M, Pham KLJ, Le AH, Liu Y, et al. First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants. Sci Rep. 2022;12(1):4163. doi:10.1038/s41598-022-07952-4.
   PubMed Web of Science ®Google Scholar
• Han Q, Wang S, Wang Z, Zhang C, Wang X, Feng N, Wang T, Zhao Y, Chi H, Yan F, et al. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models. Virol Sin. 2023. doi:10.1016/j.virs.2023.07.003.
   Web of Science ®Google Scholar
• Shen H, Cai Y, Zhang H, Wu J, Ye L, Yang P, Lin X, Jiang S, Liao M. Anti-SARS-CoV-2 IgY isolated from egg yolks of hens immunized with inactivated SARS-CoV-2 for immunoprophylaxis of COVID-19. Virol Sin. 2021;36:1080–2. doi:10.1007/s12250-021-00371-1.
   PubMed Web of Science ®Google Scholar
• Fan W, Sun S, Zhang N, Zhang Y, Jiao P, Wang J, Gao GF, Liu W, Bi Y, Yang L, et al. Nasal delivery of thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection. Sig Transduct Target Ther. 2022;7:55. doi:10.1038/s41392-022-00911-5.
   PubMed Web of Science ®Google Scholar
• Frumkin LR, Lucas M, Scribner CL, Ortega-Heinly N, Rogers J, Yin G, Hallam TJ, Yam A, Bedard K, Begley R, et al. Egg-derived anti-SARS-CoV-2 immunoglobulin Y (IgY) with broad variant activity as intranasal prophylaxis against COVID-19. Front Immunol. 2022;13:899617. doi:10.3389/fimmu.2022.899617.
   PubMed Web of Science ®Google Scholar
• Agurto-Arteaga A, Poma-Acevedo A, Rios-Matos D, Choque-Guevara R, Montesinos-Millán R, Montalván Á, Isasi-Rivas G, Cauna-Orocollo Y, Cauti-Mendoza MDG, Pérez-Martínez N, et al. Preclinical assessment of IgY antibodies against recombinant SARS-CoV-2 RBD protein for prophylaxis and post-infection treatment of COVID-19. Front Immunol. 2022;13:881604. doi:10.3389/fimmu.2022.881604.
   PubMed Web of Science ®Google Scholar
• Wouters E, Verbrugghe C, Abdelnabi R, Devloo R, De Clippel D, Jochmans D, De Bleser D, Weynand B, Compernolle V, Neyts J, et al. Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters. EBioMedicine. 2023;92:104597. doi:10.1016/j.ebiom.2023.104597.
   PubMed Web of Science ®Google Scholar
• Tada T, Minnee J, Landau NR. Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model. Proc Natl Acad Sci USA. 2023;120:e2303509120. doi:10.1073/pnas.2303509120.
   PubMed Web of Science ®Google Scholar
• Gül F, Gonen ZB, Jones OY, Taşlı NP, Zararsız G, Ünal E, Özdarendeli A, Şahin F, Eken A, Yılmaz S, et al. A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™). Front Immunol. 2022;13:963309. doi:10.3389/fimmu.2022.963309.
   PubMed Web of Science ®Google Scholar
• Focosi D, Casadevall A. A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld™) for COVID-19 prophylaxis and treatment. Viruses. 2022;14(9):14. doi:10.3390/v14091999.
   Web of Science ®Google Scholar